Aisling Capital believes the next decade will be marked
by a revolution in healthcare driven by new therapeutics
generated by biotechnology. The completion of the human
genome has given scientists new insights into the causes
of human disease. These insights, combined with the past
20 years of developments in the biotechnology industry,
are leading to rapid expansion of novel approaches
toward the diagnosis, prevention, and treatment of
life-threatening illnesses. These advances have led to
an ever-increasing demand for capital to complete the
development and commercialization of new therapeutics.
Our goal is to support the leading global healthcare companies
that are building on these technical and medical
breakthroughs to commercialize new healthcare products.